Solid Biosciences Q2 net loss widens to $39.5 mln
Overview
Solid Biosciences reports Q2 2025 net loss of $39.5 mln, up from Q2 2024
R&D expenses rose due to increased costs for SGT-003 program
Company ended Q2 2025 with $268.1 mln in cash, runway into H1 2027
Outlook
Company to discuss SGT-003 regulatory pathways with FDA in Q4 2025
Company expects SGT-212 Phase 1b trial initiation in Q4 2025
SGT-501 Phase 1b trial initiation expected in Q4 2025
Solid anticipates cash runway into H1 2027
Result Drivers
INCREASED R&D EXPENSES - R&D expenses rose due to manufacturing, regulatory, and clinical costs for SGT-003
CASH POSITION - Company ended Q2 with $268.1 mln in cash
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| -$0.42 |
|
Q2 Net Income |
| -$39.50 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Solid Biosciences Inc is $16.00, about 62% above its August 11 closing price of $6.08
Press Release: ID:nGNX7YmgF5
Related Articles
The Market Game of the Quantitative King: How Renaissance Technologies Locks in Excess Returns Amid the 2025 Turmoil
TradingKey - Founded by mathematician James Simons, Renaissance Technologies LLC is a global leader in quantitative investing, renowned for its data-driven, innovative approach. The firm eschews traditional fundamental analysis, relying instead on advanced mathematical models
Bridgewater Associates Q2 2025 13F Analysis: Founder Ray Dalio’s Final Act
TradingKey - Bridgewater Associates, the world’s largest hedge fund and renowned for its macroeconomic analysis, continues to command market respect with its “risk parity” strategy and precise economic cycle timing..jpg)
U.S. July CPI Commentary: Obstacles Cleared, Where Will U.S. Stocks Go Next?
TradingKey - On 12 August 2025, the United States released its Consumer Price Index (CPI) data for July. In terms of headline inflation, the CPI rose by 2.7% year-on-year in the month, slightly lower than the expected 2.8%. However, core CPI climbed 3.1% year-on-year, edging past the projected 3.0%.
Which Crypto Companies Are Filing for IPOs — and Who Might Be the Next Circle?
Circle’s IPO has opened the floodgates for crypto firms to tap public markets. From Gemini and Bullish to Kraken and ConsenSys, the next wave of listings is already forming.
[IN-DEPTH ANALYSIS] UnitedHealth (UNH): Can the Healthcare Giant Recover After Its Epic Collapse?
Once a Wall Street sweetheart, UnitedHealth Group (UNH) dominated the US healthcare industry with its unbeatable vertical empire, spanning insurance, clinics, pharmacies, and data analytics..jpg)
